

# **BIOPROSPECT LIMITED**

## **INVESTOR RELATIONS POLICY**

### **1. Introduction**

- 1.1 The Board of Directors (the Board) of BioProspect Limited (BioProspect) has established an Investor Relations Policy (the Policy).
- 1.2 BioProspect commits to dealing fairly, transparently and openly with both current and prospective shareholders using available channels and technologies to reach widely and communicate promptly.
- 1.3 The objectives of this Policy are to promote:
  - (a) effective communication with shareholders:
  - (b) ready access to balanced and clearly understandable information about BioProspect and:
  - (c) easy participation in general meetings.

### **2. Effective communication**

- 2.1 Our Policy is built around compliance with disclosure obligations and aspiring to be at the forefront of best practice in disclosure. Please review BioProspect's separate policy on Continuous Disclosure available on the company's web-site.
- 2.2 BioProspect will keep investors and the market fully informed of information that may have a material effect on the price or value of the company's securities by timely disclosure of information through the Australian Stock Exchange (ASX).
- 2.3 BioProspect recognises that effective communication with investors assists the creation and maintenance of an informed market in BioProspect's securities and enhances corporate governance by encouraging a culture of transparency in relation to the company's corporate proposals and activities.
- 2.4 BioProspect, where appropriate, will also provide relevant information to media companies to ensure the broadest possible communication with investors and the general market.
- 2.5 BioProspect deals with shareholder enquiries promptly and courteously and takes measures to ensure its agent, Computershare Investor services Pty Ltd, also does this.

### **3. Electronic communication**

- 3.1 BioProspect's website will be used to complement the official release of material to the market.

- 3.2 To use electronic communications effectively and enable wider access to company information by investors and stakeholders, BioProspect may:
- (a) post a summary or transcript of analyst media briefings and general meetings on BioProspect's website;
  - (b) provide information about the last two years' press releases or market announcements and at least two years of financial data on the website;
  - (c) place all relevant announcements made to the market and related information on BioProspect's website after it has been released to the ASX.
- 3.3 BioProspect encourages the use of e-mail and has built up a data base of shareholders who prefer to receive announcements such as the half yearly results via e-mail access.

#### **4. Meetings**

- 4.1 Shareholder meetings are an opportunity for shareholders and other guests to hear from and question the Board and management of BioProspect;
- 4.2 BioProspect will place the full text of notices and accompanying explanatory material on the company's website and will send notices electronically to shareholders as requested. BioProspect will distribute explanatory material by other means, so that shareholders who do not have access to the internet and other forms of electronic communication are not disadvantaged;
- 4.3 BioProspect will release full notice documentation to the ASX Announcements office;
- 4.4 BioProspect's auditor attends its Annual General Meeting and is available to answer any questions pertaining to the conduct of and any issues arising from the company's audit;
- 4.5 BioProspect conducts annual and extraordinary general meetings in accordance with the Corporations Act, the ASX Listing Rules, ASX Corporate Governance Council Best Practice Recommendations and BioProspect's constitution.

#### **5. Shareholder privacy**

- 5.1 BioProspect recognises that privacy is important and will not disclose registered shareholder details unless required by law. Shareholder details will only be used in accordance with applicable privacy laws.

#### **6. Effective date**

- 6.1 This Policy was ratified by the Board of BioProspect on 23 June 2010.